|
1
|
Wooster R, Neuhausen SL, Mangion J, Quirk
Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al:
Localization of a breast cancer susceptibility gene, BRCA2, to
chromosome 13q12-13. Science. 265:2088–2090. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoniou A, Pharoah PD, Narod S, Risch HA,
Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et
al: Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case series unselected for
family history: A combined analysis of 22 studies. Am J Hum Genet.
72:1117–1130. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lakhani SR, Manek S, Penault-Llorca F,
Flanagan A, Arnout L, Merrett S, McGuffog L, Steele D, Devilee P,
Klijn JG, et al: Pathology of ovarian cancers in BRCA1 and BRCA2
carriers. Clin Cancer Res. 10:2473–2481. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soegaard M, Kjær SK, Cox M, Wozniak E,
Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA and Ramus
SJ: BRCA1 and BRCA2 mutation prevalence and clinical
characteristics of a population-based series of ovarian cancer
cases from denmark. Clin Cancer Res. 14:3761–3767. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chetrit A, Hirsh-Yechezkel G, Ben-David Y,
Lubin F, Friedman E and Sadetzki S: Effect of BRCA1/2 mutations on
long-term survival of patients with invasive ovarian cancer: The
national Israeli study of ovarian cancer. J Clin Oncol. 26:20–25.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cass I, Baldwin RL, Varkey T, Moslehi R,
Narod SA and Karlan BY: Improved survival in women with BRCA
associated ovarian carcinoma. Cancer. 97:2187–2195. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moynahan ME, Chiu JW, Koller BH and Jasin
M: BRCA1 controls homology-directed DNA repair. Mol Cell.
4:511–518. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moynahan ME, Pierce AJ and Jasin M: BRCA2
Is required for homology-directed repair of chromosomal breaks. Mol
Cell. 7:263–272. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bolton KL, Chevenvix-Trench G, Goh C,
Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E,
Barrowdale D, McGuffog L, et al: Association between BRCA1 and
BRCA2 mutations and survival in women with invasive epithelial
ovarian cancer. JAMA. 307:382–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Audeh MW, Carmichael J, Penson RT,
Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN,
Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: A proof-of-concept trial. Lancet.
376:245–251. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nijman SM: Synthetic lethality: General
principles, utility and detection using genetic screens in human
cells. FEBS Lett. 585:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rouzbahman M and Clarke B: Neuroendocrine
tumors of the gynecologic tract: Select topics. Semin Diagn Pathol.
30:224–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gardner GJ, Reidy-Lagunes D and Gehrig PA:
Neuroendocrine tumors of the gynecologic tract: A Society of
Gynecologic Oncology (SGO) clinical document. Gynecol Oncol.
122:190–198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taube ET, Denkert C, Pietzner K, Dietel M,
Sehouli J and Darb-Esfahani S: Prognostic impact of neuroendocrine
differentiation in high-grade serous ovarian carcinoma. Virchows
Arch. 466:333–342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bhatla T, Dandekar S, Lu BY, Wang J, Han
E, Bitterman D, Jones CL, Evensen NA, Magid M, Meyer JA and Carroll
WL: Genomic characterization of poorly differentiated
neuroendocrine carcinoma in a pediatric patient. J Pediatr Hematol
Oncol. 38:e21–e25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wagner U, Harter P, Hilpert F, Mahner S,
Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, et al:
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant
Ovarian Tumors: Short version 1.0-AWMF registration number:
032/035OL, June 2013. Geburtshilfe Frauenheilkd. 73:874–889.
2013.PubMed/NCBI
|
|
18
|
Prat J; FIGO Committee on Gynecologic
Oncology, : FIGO's staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Abridged republication. J Gynecol
Oncol. 26:87–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Comprehensive Cancer Network, .
NCCN Clinical Practise Guidelines in Oncology: (NCCN) Ovarian
cvancer including fallopian tube cancer and primary peritoneal
cancer. Version 1. 2015.
|
|
20
|
Meindl A, Ditsch N, Kast K, Rhiem K and
Schmutzler RK: Hereditary breast and ovarian cancer: New genes, new
treatments, new concepts. Dtsch Arztebl Int. 108:323–330.
2011.PubMed/NCBI
|
|
21
|
Plon SE, Eccles DM, Easton D, Foulkes WD,
Genuardi M, Greenblatt MS, Hogervorst FB, Hoogerbrugge N, Sprudle
AB and Tavtigian SV and Tavtigian SV; IARC Unclassified Genetic
Variants Working Group, : Sequence variant classification and
reporting: Recommendations for improving the interpretation of
cancer susceptibility genetic test results. Hum Mutat.
29:1282–1291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Easton DF, Pharoah PD, Antoniou AC,
Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A,
Couch FJ, Southey M, et al: Gene-panel sequencing and the
prediction of breast-cancer risk. N Engl J Med. 372:2243–2257.
2015. View Article : Google Scholar : PubMed/NCBI
|
